fda warning letters glp-1 compounders september 2025 news 15, 2025: Telehealth company must stop implying its compounded GLP -1 is FDA-approved, warns – Partnership for Safe Medicines Compounded Semaglutide & Tirzepatide 2025:

"Saniona's tesofensine meets primary and secondary endpoints in Phase 3 obesity registration trial" (Press release)

It adds to the growing body of evidence suggesting that GLP-1 receptor agonists may have neuroprotective properties, which could benefit patients beyond glucose control. However, as a clinician, Im also aware of the need for further research, including longer-term studies and randomized controlled trials, to better understand the mechanisms and validate these findings before making changes to my treatment approach, she added

Nesterowicz, M

Why we love it: An easy and tasty supplement that helps maintain skin vitality from within

Pharmacokinetics and tissue distribution of gentiopicroside following oral and intravenous administration in mice